NewLimit, a South San Francisco-based startup focused on longevity, has successfully raised $435 million in its Series C funding round, which will be utilized to launch its first clinical trial for a liver medicine. The funding was spearheaded by Founders Fund, a prominent venture capital firm co-founded by Peter Thiel, and included contributions from Thrive Capital, Lilly Ventures, and tech entrepreneurs Nat Friedman and Daniel Gross. This latest financing brings NewLimit's total valuation to approximately $3.1 billion, as stated by co-founder and CEO Jacob Kimmel. Founded in 2021 by notable figures including Brian Armstrong, the CEO of Coinbase, and Blake Byers, a former partner at GV, NewLimit has gained significant traction in the longevity sector. This funding marks the third time within a year that NewLimit has attracted substantial investment, following a $130 million Series B round in May 2025 and an additional $45 million in October. The rapid pace of fundraising reflects the growing interest in longevity and health innovation.